表紙
市場調査レポート

血液脳関門:技術および世界市場

Blood-Brain Barrier Technologies and Global Markets

発行 BCC Research 商品コード 174964
出版日 ページ情報 英文 116 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
血液脳関門:技術および世界市場 Blood-Brain Barrier Technologies and Global Markets
出版日: 2014年07月28日 ページ情報: 英文 116 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

世界の血液脳関門(BBB)治療薬技術市場は2013年の2,180万米ドルとなりました。同市場は2014年から2019年にかけて64.9%のCAGRで成長し、市場額は2014年の3,870万米ドルから2019年には4億7,150万米ドルに達するとみられています。

当レポートでは、血液脳関門の概要と疾患治療、技術動向、パイプラインにおける有望薬剤動向、および参入企業のプロファイルをまとめ、概略下記の構成でお届けします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • 主要動向
  • 今日の医薬品市場
  • 医薬品業界におけるニューロフォーカス
  • 新興の血液脳関門(BBB)技術市場
  • BBBの歴史
  • 血液脳関門の定義
    • BBBの構成要素
  • BBBの図解
    • 脳の主な領域
  • 疾患治療とBBB
  • BBB技術分類
    • 最も一般的なBBB技術
    • 最も一般的に用いられる技術の課題
    • 輸送に関する考察
    • BBB技術詳細
    • 特許と知的財産保護
    • BBB技術市場:現在と将来
    • 中枢神経系における薬剤開発
    • 有望な研究内容
    • パイプラインにおけるBBB技術の潜在的使用のための有望薬剤

第4章企業プロファイル

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: PHM075B

The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.

This report provides:

  • An overview of the global market for blood-brain barrier (BBB) therapeutics and technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of CAGRs through 2019.
  • A look at how blood-brain barrier technology will impact the pharmaceutical market.
  • Information on applications, market values, growth potential, and significant trends for BBB technology.
  • Knowledge most pertinent to biotechnology and pharmaceutical industries and related life science, analytics, drug discovery, and diagnostic test manufacturing companies.
  • Profiles of leading companies in the industry.

REPORT SCOPE

SCOPE OF REPORT

The scope of this study encompasses companies that develop technologies to enable the crossing of the BBB and drug development, in which a quality of the development is enabling the crossing of the BBB, where passage was previously impossible often due to size. BCC Research analyzes each technology, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

ANALYST'S CREDENTIALS

Kim Lawson is a graduate of Mount Holyoke College with a degree in English Literature. She acquired experience as a healthcare journalist, including working for John Wiley & Sons as a print reporter, before serving as a research analyst in a small market research firm that focused on pharmaceuticals and biotechnology in the Research Triangle Park area of North Carolina. Before joining that firm, Kim published two reports on emerging and established diagnostics and therapeutics for benign and cancerous breast disease.

Table of Contents

CHAPTER 1 INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 EXECUTIVE SUMMARY

  • SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, 2012-2019 ($ MILLIONS)
    • EMERGING BBB TECHNOLOGY MARKET
    • KEY DRIVERS
    • KEY CHALLENGES

CHAPTER 3 OVERVIEW

  • MAJOR TRENDS
  • TODAY'S PHARMA MARKET
  • TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH 2017 ($ BILLIONS)
  • FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)
  • FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS)
  • FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION, 2019* ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS)
  • FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN CLINICAL DEVELOPMENT, 2019* (%)
    • BIOLOGICS
    • TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
    • GENERICS SIGNAL NEED FOR INNOVATION
  • NEUROFOCUSING IN THE PHARMA INDUSTRY
  • FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS)
  • TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 (NUMBER OF UNITS COMMERCIALIZED)
  • TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION)
  • TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
  • EMERGING BBB TECHNOLOGY MARKET
  • BRIEF HISTORY OF BBB
  • BLOOD BRAIN BARRIER DEFINED
    • BBB COMPONENTS
      • Pericytes
      • Tight Junctions
      • Lipid Barrier
      • Enzymatic Barrier
      • Efflux Pumps
  • BBB ILLUSTRATED
  • FIGURE 7 PARTS OF THE BBB
    • MAIN AREAS OF THE BRAIN
    • FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS
  • TREATING DISEASE AND THE BBB
    • MENINGITIS
    • MULTIPLE SCLEROSIS (MS)
    • ENCEPHALITIS 3
    • ALZHEIMER'S DISEASE (AD)
    • PARKINSON'S DISEASE (PD)
  • BBB TECHNOLOGY CLASSIFICATION
    • MOST COMMON BBB TECHNOLOGY
    • CHALLENGES WITH THE MOST COMMON TECHNOLOGY USED
    • TRANSPORT CONSIDERATIONS
      • Bypassing the BBB
    • BBB TECHNOLOGY DETAILED
      • Chemical Transport Systems
      • Biological Carrier or Transport Systems
      • Physical Force (Energetic) Opening Through Sound Waves (Targeted Ultrasound)
      • Enhancing Biological Transport System Techniques
      • FIGURE 9 METHODS OF CROSSING THE BBB
        • Nanoparticles and Liposomes
        • Nanoparticles
        • TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY
          • Challenges with Nanoparticles
        • Liposomes
    • PATENTS AND INTELLECTUAL PROTECTION
    • TABLE 7 KEY BBB TECHNOLOGY PATENTS
      • ArmaGen's Patent Estate
      • Life After Patenting
      • TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS ENDING 2013
    • BBB TECHNOLOGY MARKET: PRESENT AND FUTURE
    • TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS)
    • FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE, 2014* (% OF INDUSTRY)
    • FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET)
    • TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)
    • FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)
    • TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL METHOD
    • TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET
      • Genzyme Innovates and Sells Technology to Pharmidex
    • DRUG DEVELOPMENT IN THE CNS
      • Multiple Models Must Be Used
      • BBB Is Its Own Site of Investigation
      • Understanding Interactions and Brain Areas as Distinct
      • TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB TECHNOLOGIES
      • What Values Are Best
      • TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL EFFECTS
    • PROMISING RESEARCH
    • PROMISING CNS DRUGS THAT ARE LATER STAGE IN THE DEVELOPMENT PIPELINE FOR POTENTIAL USE WITH BBB TECHNOLOGY
      • Brain Cancer
      • TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019
      • Anxiety
      • TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019
      • Dementia
      • TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019
      • Parkinson's disease
      • TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019
      • Depression
      • TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019
      • Personality/Psychiatric Disorders (Schizophrenia/bipolar)
      • TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019
      • Spinal Cord Injury
      • TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019
      • Addiction Disorders
      • TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019
      • Attention Deficit Hyperactivity Disorder (ADHD)
      • TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER, THROUGH 2019
      • Sleep Disorders
      • TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019

CHAPTER 4 COMPANY PROFILES

  • ABLYNX
  • ADENIOS
  • ANGIOCHEM
  • ARMAGEN TECHNOLOGIES
  • BIOASIS TECHNOLOGIES
  • BRISTOL-MYERS SQUIBB
  • CAPSULUTION PHARMA
  • DAINIPPON SUMITOMO PHARMA
  • ELI LILLY AND COMPANY
  • EUTHYMICS BIOSCIENCE
  • FABRE-KRAMER PHARMACEUTICALS
  • FLOCEL
  • FORUM PHARMACEUTICALS
  • GENZYME
  • INSIGHTEC
  • INTERNATIONAL BRAIN BARRIERS SOCIETY (IBBS)
  • ISIS INNOVATION
  • JANSSEN PHARMACEUTICA
  • H LUNDBECK
  • MEDGENESIS THERAPEUTIX (BIOVAIL LAB)
  • MEDIMMUNE
  • MEDINVENT
  • NANOMERICS
  • NEUROVIVE PHARMACEUTICAL
  • NEUREN PHARMACEUTICALS
  • NSGENE
  • OPTINOSE
  • OSSIANIX
  • OTSUKA AMERICA PHARMACEUTICAL
  • PROTHENA CORP
  • PROTHERAGEN
  • PFIZER
  • PHARMACO-CELL
  • PHARMIDEX
  • RAPTOR PHARMACEUTICAL
  • ROCHE
  • ROYALTY PHARMA
  • SHIRE
  • SANERON CCEL THERAPEUTICS
  • SOLVO BIOTECHNOLOGY
  • SOVICELL
  • TEVA PHARMACEUTICAL INDUSTRIES
  • TO-BBB TECHNOLOGIES
  • TTY BIOPHARM
  • UCB
  • VECT-HORUS
  • XENOPORT
  • XIGEN

LIST OF TABLES

  • SUMMARY TABLE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
  • TABLE 1 PHARMACEUTICAL DRUGS MARKET BY GEOGRAPHICAL REGION, THROUGH 2017 ($ BILLIONS)
  • TABLE 2 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
  • TABLE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, THROUGH 2019 (NUMBER OF UNITS COMMERCIALIZED)
  • TABLE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY POSSIBLE CNS INDICATION, 2014 AND 2019 (NUMBER OF UNITS PER INDICATION)
  • TABLE 5 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
  • TABLE 6 DESIRABLE NANOPARTICLE QUALITIES TO ACT AS BBB TECHNOLOGY
  • TABLE 7 KEY BBB TECHNOLOGY PATENTS
  • TABLE 8 SAMPLE OF FINANCIAL DEALS IN CNS THERAPEUTICS IN THE FIVE YEARS ENDING 2013
  • TABLE 9 SAMPLE OF FINANCIAL DEALS IN BBB TECHNOLOGY RECEIVED THROUGH PHARMACEUTICAL COMPANY (ESTIMATED, $ MILLIONS)
  • TABLE 10 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)
  • TABLE 11 BBB TECHNOLOGY COMPANIES AND RESPECTIVE TECHNOLOGICAL METHOD
  • TABLE 12 BBB TECHNOLOGY COMPANIES AND CORPORATE PARTNERS/LICENSING DEALS OR LARGE INVESTMENT WITH LEAD DISEASE TARGET
  • TABLE 13 SUCCESS FACTORS IN CNS DRUG DEVELOPMENT USING BBB TECHNOLOGIES
  • TABLE 14 FREQUENT DRUG DEVELOPMENT CHALLENGES AND THEIR CLINICAL EFFECTS
  • TABLE 15 GLOBAL PIPELINE FOR BRAIN CANCER, THROUGH 2019
  • TABLE 16 GLOBAL PIPELINE FOR ANXIETY DISORDER, THROUGH 2019
  • TABLE 17 GLOBAL PIPELINE FOR ALZHEIMER'S DISEASE, THROUGH 2019
  • TABLE 18 GLOBAL PIPELINE FOR PARKINSON'S DISEASE, THROUGH 2019
  • TABLE 19 GLOBAL PIPELINE FOR DEPRESSION, THROUGH 2019
  • TABLE 20 GLOBAL PIPELINE FOR SCHIZOPHRENIA, THROUGH 2019
  • TABLE 21 GLOBAL PIPELINE FOR SPINAL CORD INJURY, THROUGH 2019
  • TABLE 22 GLOBAL PIPELINE FOR ADDICTION DISORDERS, THROUGH 2019
  • TABLE 23 GLOBAL PIPELINE FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER, THROUGH 2019
  • TABLE 24 GLOBAL PIPELINE FOR SLEEP DISORDERS, THROUGH 2019

LIST OF FIGURES

  • SUMMARY FIGURE GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, 2012-2019 ($ MILLIONS)
  • FIGURE 1 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)
  • FIGURE 2 EMERGING REGIONS' PHARMACEUTICAL MARKET SHARES COMPARED TO THE U.S. AND EUROPE, 2017 (ESTIMATED $BILLIONS)
  • FIGURE 3 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY REGION, 2019* ($ MILLIONS)
  • FIGURE 4 GLOBAL MARKET FOR BBB TECHNOLOGY FOR THERAPEUTICS, BY THERAPEUTIC AREA, 2019* (% OF ALL SALES FROM COMMERCIALIZED DRUGS)
  • FIGURE 5 MOST FREQUENT BBB TARGET AREAS FOR COMPANIES WITH DRUGS IN CLINICAL DEVELOPMENT, 2019* (%)
  • FIGURE 6 CNS REVENUE DISTRIBUTION BY DISEASE TARGET, 2012 ($ BILLIONS)
  • FIGURE 7 PARTS OF THE BBB
  • FIGURE 8 THE BRAIN: BBB PROTECTS AND BRIDGES IT TO BLOOD VESSELS
  • FIGURE 9 METHODS OF CROSSING THE BBB
  • FIGURE 10 COMPOSITION OF BBB TECHNOLOGY INDUSTRY BY TECHNOLOGY TYPE, 2014* (% OF INDUSTRY)
  • FIGURE 11 COMPOSITION OF BBB TECHNOLOGY BY TECHNOLOGY TYPE IN THE COMMERCIALIZED (THERAPEUTIC DRUG) MARKET, 2019 (% OF MARKET)
  • FIGURE 12 DRUGS IN DEVELOPMENT USING BBB-PASSAGE TECHNOLOGY, 2014 AND 2019 (NUMBER OF UNITS)
Back to Top